New Indication: Neoadjuvant Nivolumab for NSCLC

Open-label, phase 3 trial

Stage IB to IIIA resectable NSCLC

Three cycles neoadjuvant treatment

Nivolumab plus platinum-based chemotherapy (n=176) or platinum-based chemotherapy (n=176)

mEFS: 31.6 m vs 20.8 m (HR:0.63; 97.38% CI, 0.43 to 0.91; P=0.005)

pCR: 24.0% vs 2.2% (OR:13.94; 99% CI, 3.49 to 55.75; P<0.001)

mOS: NR vs NR (HR: 0.57; 99.67% CI, 0.30 to 1.07; P=0.008)

Grade >= 3 AEs: 33.5% vs 36.9%

Grade >=3 AEs neutropenia:8.5% vs 11.9%

Discontinuation of treatment 10.2% vs 9.7%

Reviewed by Hasan Cagri Yildirim, MD on Sep 20, 2022

nivolumab